A 37-year-old woman presented with an 18-month history of malaise, mouth ulcers, and arthralgias. From the age of 18 she had a persistent telangiectatic facial rash, similar to that of systemic lupus erythematosus, and from the age of 25 she had recurrent migraine and frequent episodes of bronchitis with asthma. Skin tests to common allergens were negative, but there was a strong family history of atopic disease. Full blood count and complement levels were normal, the erythrocyte sedimentation rate was 4 mm/lst h, and rheumatoid factor and antinuclear antibody tests were negative. Parotid secretion studies and labial salivary gland biopsy were normal, and skin biopsy did not show immunoglobulin deposition. She was considered to have an undifferentiated connective tissue disorder and received trials of hydroxychloroquine and chloroquine without benefit. After she complained of nausea and blurred vision the chloroquine was stopped. Liver function tests were normal, and mepacrine was substituted at a dose of 100 mg daily, increasing after two weeks to 300 mg daily. The patient was warned of the possibility of skin yellowing. Six weeks later she reported that her skin and eyes had abruptly turned yellow accompanied by feelings of lethargy, loss of appetite, itching and tender cervical lymphadenopathy. She was instructed to stop the mepacrine, but four weeks later her urine contained urobilinogen, her y-glutamyltransferase was 264 IU/l (normal (n)<65 IU/l), alanine transaminase 210 IU/I (n<45 IU/l), aspartase transaminase 107 IU/I (n<41 IU/l), and alkaline phosphatase 160 IU/l (n<105 IU/l). However, the bilirubin (5 [tmolUl) was normal, indicating that she was not jaundiced. An absolute eosinophil count of 680/mm3 (0-68x l09/l) was noted. Serological tests for hepatitis A and B and cytomegalovirus were negative. Further investigations were considered unnecessary as the liver function tests gradually improved and after two months were normal. The skin and sclerae remained yellow for two months after mepacrine was stopped.
In this patient the systemic symptoms, scleral yellowing, and urinary urobilinogen suggested hepatitis. The liver function tests supported this diagnosis, but the normal bilirubin indicated that the yellow discoloration was due to mepacrine. Mepacrine hepatitis associated with therapeutic doses is an idiosyncratic, unpredictable reaction similar to that caused by halothane. In addition to eosinophilia and lymphadenopathy, fever, rashes, and arthralgias may occur, features commonly found in the connective tissue diseases. Liver histology is similar to viral hepatitis2 or acute massive necrosis may result) The precise pharmacokinetics of mepacrine are not known but, like its fellow 4-aminoquinoline, chloroquine, it has an unusually large volume of distribution being widely distributed and bound in liver, lungs, spleen, adrenal, skin, and leucocytes. cult to accept that, while haematologists obtain ten year 4'cures" in malignant B-lymphoproliferative disease, only a minority of patients with classical RA . a non-malignant B-lymphoproliferative disease-will experience any remission on a single drug chemotherapy. 2 The potential for provoking a cure in RA has enormous implications. However, the selection for chemotherapy trials of only those patients with long-established disease, who have failed on 'conventional' therapy, will produce in all likelihood an equivocal answer. Such patients will already have suffered severe and irreversible joint destruction, and we should be aiming to produce the cure long before this stage. By analogy, in lymphoma the later the treatment is given the less effective it is.
The evidence is pretty clear that patients with seropositive erosive RA who are DR-4 positive are going to do badly. I 
